Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Serotonin-Norepinephrine reuptake inhibitors

13 evidence topics · 9 sources

Venlafaxine extended-release: HAM-A results of the four adult GAD studies
Study and treatment groupLS mean change from baseline (SE)Placebo-subtracted difference (95% CI)
Study 1, venlafaxine XR 75 mg“-11.1 (0.95)”“-1.5 (-3.8, 0.8)”
Study 1, venlafaxine XR 150 mg“-11.7 (0.87)”“-2.2 (-4.5, 0.1)”
Study 1, venlafaxine XR 225 mg“-12.1 (0.81)”“-2.6 (-4.9, -0.3)”
Study 1, placebo“-9.5 (0.85)”
Study 2, venlafaxine XR 75 mg“-10.6 (0.82)”“-2.6 (-4.6, -0.5)”
Study 2, venlafaxine XR 150 mg“-9.8 (0.86)”“-1.7 (-3.8, 0.3)”
Study 2, placebo“-8.0 (0.73)”
Study 3, venlafaxine XR 37.5 mg“-13.8”“-2.8 (-5.1, -0.6)”
Study 3, venlafaxine XR 75 mg“-15.5”“-4.6 (-6.9, -2.3)”
Study 3, venlafaxine XR 150 mg“-16.4”“-5.5 (-7.8, -3.1)”
Study 3, placebo“-11.0”
Study 4, venlafaxine XR 75-225 mg“-13.4 (0.79)”“- 4.7 (-6.6, -2.9)”
Study 4, placebo“-8.7 (0.70)”
FDA-approved GAD indication: duloxetine

“Generalized anxiety disorder in adults and pediatric patients 7 years of age and older” (opens the source at this quote in a new tab)

“For most adults less than 65 years of age with GAD, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to CYMBALTA before increasing to 60 mg once daily. While a 120 mg once daily dosage was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit.” (opens the source at this quote in a new tab)

“The efficacy of CYMBALTA in the treatment of generalized anxiety disorder (GAD) was established in 1 fixed-dose randomized, double-blind, placebo-controlled trial and 2 flexible-dose randomized, double-blind, placebo-controlled trials in adult outpatients between 18 and 83 years of age meeting the DSM-IV criteria for GAD (Studies GAD-1, GAD-2, and GAD-3, respectively).” (opens the source at this quote in a new tab)

“In all 3 trials, CYMBALTA demonstrated superiority over placebo as measured by greater improvement in the Hamilton Anxiety Scale (HAM-A) total score (see Table 8) and by the Sheehan Disability Scale (SDS) global functional impairment score.” (opens the source at this quote in a new tab)

“Patients treated with CYMBALTA (N=151) demonstrated significantly greater improvement compared with placebo (N=140) on mean change from baseline to endpoint as measured by the HAM-A total score (see Table 8).” (opens the source at this quote in a new tab)

Adverse reactions and discontinuation with venlafaxine extended-release

“The most commonly observed adverse reactions in the clinical study database in Effexor XR treated patients in MDD, GAD, SAD, and PD (incidence ≥5% and at least twice the rate of placebo) were: nausea (30.0%), somnolence (15.3%), dry mouth (14.8%), sweating (11.4%), abnormal ejaculation (9.9%), anorexia (9.8%), constipation (9.3%), impotence (5.3%), and decreased libido (5.1%).” (opens the source at this quote in a new tab)

“Combined across short-term, placebo-controlled premarketing studies for all indications, 12% of the 3,558 patients who received Effexor XR (37.5-225 mg) discontinued treatment due to an adverse experience, compared with 4% of the 2,197 placebo-treated patients in those studies.” (opens the source at this quote in a new tab)

“In controlled trials, there were dose-related increases in systolic and diastolic blood pressure, as well as cases of sustained hypertension” (opens the source at this quote in a new tab)

“Monitor blood pressure before initiating treatment with Effexor XR and regularly during treatment.” (opens the source at this quote in a new tab)

“Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment.” (opens the source at this quote in a new tab)

Adverse reactions and discontinuation with duloxetine

“Approximately 13.7% (139/1018) of the CYMBALTA-treated patients in placebo-controlled adult trials for GAD discontinued treatment due to an adverse reaction, compared with 5% (38/767) for placebo-treated patients.” (opens the source at this quote in a new tab)

“Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included nausea (CYMBALTA 3.3%, placebo 0.4%), and dizziness (CYMBALTA 1.3%, placebo 0.4%).” (opens the source at this quote in a new tab)

“The most commonly observed adverse reactions in CYMBALTA-treated patients in all the pooled adult populations (i.e., MDD, GAD, DPNP, FM, OA, and CLBP) (incidence of at least 5% and at least twice the incidence in placebo-treated patients) were nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis.” (opens the source at this quote in a new tab)

“There have been reports of hepatic failure, sometimes fatal, in patients treated with CYMBALTA.” (opens the source at this quote in a new tab)

“Following abrupt or tapered discontinuation in adult placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in CYMBALTA-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue.” (opens the source at this quote in a new tab)

Relapse after discontinuation: meta-analysis of relapse prevention trials, SNRI subgroup
SubgroupNumber of studiesOdds ratio of relapse, placebo relative to continued antidepressant (95% CI)
SNRI“3”View highlighted excerpt for this quote“5.03 (1.31 to 19.40)”View highlighted excerpt for this quote